AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced the presentation of new preclinical data ...

antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. GB261 has been licensed to JHBP holding and will enter into phase 1 clinical trials soon. The design of ...

an anti-CD25 antibody that drives the antibody-dependent cellular cytotoxicity response towards immune-suppressive regulatory T cells (T reg cells) in cancer. The company has a two-pronged ...

The investigators showed that in vivo gene therapy in mice mediated the destruction of human eosinophils and antibody-dependent cellular cytotoxicity activity against human eosinophils.

Table 1. The types and characteristics of FcγRs. Source: Sino Biological Inc. To mediate antibody-dependent cellular cytotoxicity (ADCC), NK cells recognize cell-bound antibodies via CD16A ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

It interferes with the immune response by binding to the IgG1 CH3 domain, suppressing critical mechanisms like complement-mediated tumor killing and antibody-dependent cellular cytotoxicity.

As of Tuesday, April 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 7.59%, which has investors questioning if this is right time to sell.

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

Additionally, IBI3019 incorporates a high-affinity CD16A nanobody that showed better antibody-dependent cell cytotoxicity than those mediated by low-fucose Fc. Importantly, IBI3019 not only ...